Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors.

Webber BR, Lonetree CL, Kluesner MG, Johnson MJ, Pomeroy EJ, Diers MD, Lahr WS, Draper GM, Slipek NJ, Smeester BA, Lovendahl KN, McElroy AN, Gordon WR, Osborn MJ, Moriarity BS.

Nat Commun. 2019 Dec 6;10(1):5659. doi: 10.1038/s41467-019-13778-y.

2.

Phenotype categorization of neurofibromatosis type I and correlation to NF1 mutation types.

Kang E, Kim YM, Seo GH, Oh A, Yoon HM, Ra YS, Kim EK, Kim H, Heo SH, Kim GH, Osborn MJ, Tolar J, Yoo HW, Lee BH.

J Hum Genet. 2020 Jan;65(2):79-89. doi: 10.1038/s10038-019-0695-0. Epub 2019 Nov 28.

PMID:
31776437
3.

Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors.

Webber BR, Lonetree CL, Kluesner MG, Johnson MJ, Pomeroy EJ, Diers MD, Lahr WS, Draper GM, Slipek NJ, Smeester BA, Lovendahl KN, McElroy AN, Gordon WR, Osborn MJ, Moriarity BS.

Nat Commun. 2019 Nov 19;10(1):5222. doi: 10.1038/s41467-019-13007-6. Erratum in: Nat Commun. 2019 Dec 6;10(1):5659.

4.

Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy.

Kim YM, Yum MS, Heo SH, Kim T, Jin HK, Bae JS, Seo GH, Oh A, Yoon HM, Lim HT, Kim HW, Ko TS, Lim HS, Osborn MJ, Tolar J, Cozma C, Rolfs A, Zimran A, Lee BH, Yoo HW.

J Med Genet. 2020 Feb;57(2):124-131. doi: 10.1136/jmedgenet-2019-106132. Epub 2019 Oct 24.

5.

Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality.

Saha A, Taylor PA, Lees CJ, Panoskaltsis-Mortari A, Osborn MJ, Feser CJ, Thangavelu G, Melchinger W, Refaeli Y, Hill GR, Munn DH, Murphy WJ, Serody JS, Maillard I, Kreymborg K, van den Brink M, Dong C, Huang S, Zang X, Allison JP, Zeiser R, Blazar BR.

JCI Insight. 2019 Oct 3;4(19). pii: 127716. doi: 10.1172/jci.insight.127716.

6.

The Way It Was.

Osborn MJ.

Annu Rev Microbiol. 2019 Sep 8;73:1-15. doi: 10.1146/annurev-micro-020518-115834.

PMID:
31500534
7.

Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs.

Osborn MJ, Newby GA, McElroy AN, Knipping F, Nielsen SC, Riddle MJ, Xia L, Chen W, Eide CR, Webber BR, Wandall HH, Dabelsteen S, Blazar BR, Liu DR, Tolar J.

J Invest Dermatol. 2020 Feb;140(2):338-347.e5. doi: 10.1016/j.jid.2019.07.701. Epub 2019 Aug 19.

PMID:
31437443
8.

Hematotherapy: Pioneers and Pathfinders.

Osborn MJ.

Stem Cells Dev. 2019 Jun 1;28(11):707. doi: 10.1089/scd.2019.0076. Epub 2019 May 13. No abstract available.

PMID:
31081717
9.

Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies.

Clarke SC, Ma B, Trinklein ND, Schellenberger U, Osborn MJ, Ouisse LH, Boudreau A, Davison LM, Harris KE, Ugamraj HS, Balasubramani A, Dang KH, Jorgensen B, Ogana HAN, Pham DT, Pratap PP, Sankaran P, Anegon I, van Schooten WC, Brüggemann M, Buelow R, Force Aldred S.

Front Immunol. 2019 Jan 7;9:3037. doi: 10.3389/fimmu.2018.03037. eCollection 2018.

10.

Stroke in patients with cardiovascular implantable electronic device infection undergoing transvenous lead removal.

Lee JZ, Agasthi P, Pasha AK, Tarin C, Tseng AS, Diehl NN, Hodge DO, DeSimone CV, Killu AM, Brady PA, Kancharla K, Kusumoto FM, Srivathsan K, Osborn MJ, Espinosa RE, Rea RF, Madhavan M, McLeod CJ, Shen WK, Cha YM, Friedman PA, Asirvatham SJ, Mulpuru SK.

Heart Rhythm. 2018 Nov;15(11):1593-1600. doi: 10.1016/j.hrthm.2018.08.008.

PMID:
30654978
11.

The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease.

McDonald-Hyman C, Muller JT, Loschi M, Thangavelu G, Saha A, Kumari S, Reichenbach DK, Smith MJ, Zhang G, Koehn BH, Lin J, Mitchell JS, Fife BT, Panoskaltsis-Mortari A, Feser CJ, Kirchmeier AK, Osborn MJ, Hippen KL, Kelekar A, Serody JS, Turka LA, Munn DH, Chi H, Neubert TA, Dustin ML, Blazar BR.

J Clin Invest. 2018 Oct 1;128(10):4604-4621. doi: 10.1172/JCI95713. Epub 2018 Aug 14.

12.

Incidence, patterns, and outcomes after transvenous cardiac device lead macrodislodgment: Insights from a population-based study.

Tseng AS, Shipman JN, Lee JZ, Mi L, Amin M, Killu AM, Deshmukh AJ, Madhavan M, McLeod CJ, Srivathsan KK, Shen WK, Osborn MJ, Cha YM, Asirvatham SJ, Friedman PA, Mulpuru SK.

Heart Rhythm. 2019 Jan;16(1):140-147. doi: 10.1016/j.hrthm.2018.07.026. Epub 2018 Jul 25. No abstract available.

PMID:
30053613
13.

Outcomes of video-assisted thoracoscopic surgery for transvenous lead extraction.

Dai M, Joyce DL, Blackmon S, Friedman MPHPA, Espinosa R, Osborn MJ, Huang C, Cha YM.

J Cardiovasc Electrophysiol. 2018 Jul;29(7):1032-1037. doi: 10.1111/jce.13643. Epub 2018 Jun 14.

PMID:
29858883
14.

Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.

Pennell CA, Barnum JL, McDonald-Hyman CS, Panoskaltsis-Mortari A, Riddle MJ, Xiong Z, Loschi M, Thangavelu G, Campbell HM, Storlie MD, Refaeli Y, Furlan SN, Jensen MC, Kean LS, Miller JS, Tolar J, Osborn MJ, Blazar BR.

Mol Ther. 2018 Jun 6;26(6):1423-1434. doi: 10.1016/j.ymthe.2018.04.006. Epub 2018 Apr 7.

15.

Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa.

Vanden Oever M, Twaroski K, Osborn MJ, Wagner JE, Tolar J.

Pediatr Res. 2018 Jan;83(1-2):318-324. doi: 10.1038/pr.2017.244. Epub 2017 Nov 1. Review.

PMID:
29593249
16.

CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression.

Osborn MJ, Lees CJ, McElroy AN, Merkel SC, Eide CR, Mathews W, Feser CJ, Tschann M, McElmury RT, Webber BR, Kim CJ, Blazar BR, Tolar J.

Int J Mol Sci. 2018 Mar 22;19(4). pii: E946. doi: 10.3390/ijms19040946.

17.

Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.

Yoon DH, Osborn MJ, Tolar J, Kim CJ.

Int J Mol Sci. 2018 Jan 24;19(2). pii: E340. doi: 10.3390/ijms19020340. Review.

18.

Prokaryotic soluble expression and purification of bioactive human fibroblast growth factor 21 using maltose-binding protein.

Nguyen AN, Song JA, Nguyen MT, Do BH, Kwon GG, Park SS, Yoo J, Jang J, Jin J, Osborn MJ, Jang YJ, Thi Vu TT, Oh HB, Choe H.

Sci Rep. 2017 Nov 23;7(1):16139. doi: 10.1038/s41598-017-16167-x.

19.

Rapid generation of Col7a1-/- mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells.

Webber BR, O'Connor KT, McElmurry RT, Durgin EN, Eide CR, Lees CJ, Riddle MJ, Mathews WE, Frank NY, Kluth MA, Ganss C, Moriarity BS, Frank MH, Osborn MJ, Tolar J.

Lab Invest. 2017 Oct;97(10):1218-1224. doi: 10.1038/labinvest.2017.85. Epub 2017 Sep 11.

20.

Granulocyte colony-stimulating factor (GCSF) fused with Fc Domain produced from E. coli is less effective than Polyethylene Glycol-conjugated GCSF.

Do BH, Kang HJ, Song JA, Nguyen MT, Park S, Yoo J, Nguyen AN, Kwon GG, Jang J, Jang M, Lee S, So S, Sim S, Lee KJ, Osborn MJ, Choe H.

Sci Rep. 2017 Jul 25;7(1):6480. doi: 10.1038/s41598-017-06726-7.

21.

CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells.

Skvarova Kramarzova K, Osborn MJ, Webber BR, DeFeo AP, McElroy AN, Kim CJ, Tolar J.

Int J Mol Sci. 2017 Jun 14;18(6). pii: E1269. doi: 10.3390/ijms18061269.

22.

Genome-wide Specificity of Highly Efficient TALENs and CRISPR/Cas9 for T Cell Receptor Modification.

Knipping F, Osborn MJ, Petri K, Tolar J, Glimm H, von Kalle C, Schmidt M, Gabriel R.

Mol Ther Methods Clin Dev. 2017 Feb 12;4:213-224. doi: 10.1016/j.omtm.2017.01.005. eCollection 2017 Mar 17.

23.

Strategies to Obtain Diverse and Specific Human Monoclonal Antibodies From Transgenic Animals.

Brüggemann M, Osborn MJ, Ma B, Buelow R.

Transplantation. 2017 Aug;101(8):1770-1776. doi: 10.1097/TP.0000000000001702. Review.

PMID:
28230642
24.

Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology.

Osborn MJ, Webber BR, McElmurry RT, Rudser KD, DeFeo AP, Muradian M, Petryk A, Hallgrimsson B, Blazar BR, Tolar J, Braunlin EA.

J Inherit Metab Dis. 2017 Mar;40(2):281-289. doi: 10.1007/s10545-016-9988-z. Epub 2016 Oct 14.

25.

Gene editing and its application for hematological diseases.

Osborn MJ, Belanto JJ, Tolar J, Voytas DF.

Int J Hematol. 2016 Jul;104(1):18-28. doi: 10.1007/s12185-016-2017-z. Epub 2016 May 27. Review.

26.

CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa.

Webber BR, Osborn MJ, McElroy AN, Twaroski K, Lonetree CL, DeFeo AP, Xia L, Eide C, Lees CJ, McElmurry RT, Riddle MJ, Kim CJ, Patel DD, Blazar BR, Tolar J.

NPJ Regen Med. 2016;1. pii: 16014. doi: 10.1038/npjregenmed.2016.14. Epub 2016 Dec 8.

27.

Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases.

Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, McElroy AN, Starker CG, Lee C, Merkel S, Lund TC, Kelly-Spratt KS, Jensen MC, Voytas DF, von Kalle C, Schmidt M, Gabriel R, Hippen KL, Miller JS, Scharenberg AM, Tolar J, Blazar BR.

Mol Ther. 2016 Mar;24(3):570-81. doi: 10.1038/mt.2015.197. Epub 2015 Oct 27.

28.

Outcomes and Complications of Lead Removal: Can We Establish a Risk Stratification Schema for a Collaborative and Effective Approach?

Fu HX, Huang XM, Zhong LI, Osborn MJ, Asirvatham SJ, Espinosa RE, Brady PA, Lee HC, Greason KL, Baddour LM, Sohail RM, Acker NG, Hodge DO, Friedman PA, Cha YM.

Pacing Clin Electrophysiol. 2015 Dec;38(12):1439-47. doi: 10.1111/pace.12736. Epub 2015 Sep 22. Erratum in: Pacing Clin Electrophysiol. 2016 Feb;39(2):205.

PMID:
26293652
29.

Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.

Perdoni C, Osborn MJ, Tolar J.

Transl Res. 2016 Feb;168:50-58. doi: 10.1016/j.trsl.2015.05.008. Epub 2015 May 27. Review.

30.

Reply to the Editor--Re: Extraction of nonfunctional leads at the time of device upgrade: Still unproven benefit compared to abandoning leads.

Huang XM, Fu H, Osborn MJ, Asirvatham SJ, McLeod CJ, Glickson M, Acker NG, Friedman PA, Cha YM.

Heart Rhythm. 2015 Jul;12(7):e65-6. doi: 10.1016/j.hrthm.2015.03.063. Epub 2015 Mar 31. No abstract available.

PMID:
25835466
31.

B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality.

Veenstra RG, Flynn R, Kreymborg K, McDonald-Hyman C, Saha A, Taylor PA, Osborn MJ, Panoskaltsis-Mortari A, Schmitt-Graeff A, Lieberknecht E, Murphy WJ, Serody JS, Munn DH, Freeman GJ, Allison JP, Mak TW, van den Brink M, Zeiser R, Blazar BR.

Blood. 2015 May 21;125(21):3335-46. doi: 10.1182/blood-2014-09-603357. Epub 2015 Mar 26. Erratum in: Blood. 2016 Jun 16;127(24):3104.

32.

Extraction of superfluous device leads: A comparison with removal of infected leads.

Huang XM, Fu H, Osborn MJ, Asirvatham SJ, McLeod CJ, Glickson M, Acker NG, Friedman PA, Cha YM.

Heart Rhythm. 2015 Jun;12(6):1177-82. doi: 10.1016/j.hrthm.2015.02.005. Epub 2015 Feb 7.

PMID:
25661776
33.

Fanconi anemia gene editing by the CRISPR/Cas9 system.

Osborn MJ, Gabriel R, Webber BR, DeFeo AP, McElroy AN, Jarjour J, Starker CG, Wagner JE, Joung JK, Voytas DF, von Kalle C, Schmidt M, Blazar BR, Tolar J.

Hum Gene Ther. 2015 Feb;26(2):114-26. doi: 10.1089/hum.2014.111.

34.

Human antibody production in transgenic animals.

Brüggemann M, Osborn MJ, Ma B, Hayre J, Avis S, Lundstrom B, Buelow R.

Arch Immunol Ther Exp (Warsz). 2015 Apr;63(2):101-8. doi: 10.1007/s00005-014-0322-x. Epub 2014 Dec 3. Review.

35.

Femoral approach to lead extraction.

Mulpuru SK, Hayes DL, Osborn MJ, Asirvatham SJ.

J Cardiovasc Electrophysiol. 2015 Mar;26(3):357-61. doi: 10.1111/jce.12564. Epub 2014 Nov 11. Review.

PMID:
25311643
36.

Outcome and management of pacemaker-induced superior vena cava syndrome.

Fu HX, Huang XM, Zhong L, Osborn MJ, Bjarnason H, Mulpuru S, Zhao XX, Friedman PA, Cha YM.

Pacing Clin Electrophysiol. 2014 Nov;37(11):1470-6. doi: 10.1111/pace.12455. Epub 2014 Jul 17.

PMID:
25040311
37.

Outcomes of lead revision for myocardial perforation after cardiac implantable electronic device placement.

Huang XM, Fu HX, Zhong L, Osborn MJ, Asirvatham SJ, Sinak LJ, Cao J, Friedman PA, Cha YM.

J Cardiovasc Electrophysiol. 2014 Oct;25(10):1119-24. doi: 10.1111/jce.12457. Epub 2014 Jul 7.

PMID:
24863054
38.

Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa.

Tolar J, McGrath JA, Xia L, Riddle MJ, Lees CJ, Eide C, Keene DR, Liu L, Osborn MJ, Lund TC, Blazar BR, Wagner JE.

J Invest Dermatol. 2014 May;134(5):1246-1254. doi: 10.1038/jid.2013.523. Epub 2013 Dec 6.

39.

Human antibody expression in transgenic rats: comparison of chimeric IgH loci with human VH, D and JH but bearing different rat C-gene regions.

Ma B, Osborn MJ, Avis S, Ouisse LH, Ménoret S, Anegon I, Buelow R, Brüggemann M.

J Immunol Methods. 2013 Dec 31;400-401:78-86. doi: 10.1016/j.jim.2013.10.007. Epub 2013 Oct 30.

40.

Pacemaker lead perforation causing hemopericardium eight years after implantation.

Liang JJ, Killu AM, Osborn MJ, Jaffe AS.

Indian Heart J. 2013 May-Jun;65(3):331-3. doi: 10.1016/j.ihj.2013.04.009. Epub 2013 Apr 9.

41.

Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responses.

Dietz WM, Skinner NE, Hamilton SE, Jund MD, Heitfeld SM, Litterman AJ, Hwu P, Chen ZY, Salazar AM, Ohlfest JR, Blazar BR, Pennell CA, Osborn MJ.

Mol Ther. 2013 Aug;21(8):1526-35. doi: 10.1038/mt.2013.85. Epub 2013 May 21.

42.

TALEN-based gene correction for epidermolysis bullosa.

Osborn MJ, Starker CG, McElroy AN, Webber BR, Riddle MJ, Xia L, DeFeo AP, Gabriel R, Schmidt M, von Kalle C, Carlson DF, Maeder ML, Joung JK, Wagner JE, Voytas DF, Blazar BR, Tolar J.

Mol Ther. 2013 Jun;21(6):1151-9. doi: 10.1038/mt.2013.56. Epub 2013 Apr 2.

43.

High-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igκ/Igλ loci bearing the rat CH region.

Osborn MJ, Ma B, Avis S, Binnie A, Dilley J, Yang X, Lindquist K, Ménoret S, Iscache AL, Ouisse LH, Rajpal A, Anegon I, Neuberger MS, Buelow R, Brüggemann M.

J Immunol. 2013 Feb 15;190(4):1481-90. doi: 10.4049/jimmunol.1203041. Epub 2013 Jan 9. Erratum in: J Immunol. 2013 Jun 15;190(12):6707.

44.

Targeting G with TAL effectors: a comparison of activities of TALENs constructed with NN and NK repeat variable di-residues.

Christian ML, Demorest ZL, Starker CG, Osborn MJ, Nyquist MD, Zhang Y, Carlson DF, Bradley P, Bogdanove AJ, Voytas DF.

PLoS One. 2012;7(9):e45383. doi: 10.1371/journal.pone.0045383. Epub 2012 Sep 24.

45.

Keratinocytes from induced pluripotent stem cells in junctional epidermolysis bullosa.

Tolar J, Xia L, Lees CJ, Riddle M, McElroy A, Keene DR, Lund TC, Osborn MJ, Marinkovich MP, Blazar BR, Wagner JE.

J Invest Dermatol. 2013 Feb;133(2):562-5. doi: 10.1038/jid.2012.278. Epub 2012 Aug 30. No abstract available.

46.

Outcomes and predictors of difficulty with coronary sinus lead removal.

Sheldon S, Friedman PA, Hayes DL, Osborn MJ, Cha YM, Rea RF, Asirvatham SJ.

J Interv Card Electrophysiol. 2012 Oct;35(1):93-100. doi: 10.1007/s10840-012-9685-2. Epub 2012 May 15.

PMID:
22584767
47.

Synthetic zinc finger nuclease design and rapid assembly.

Osborn MJ, DeFeo AP, Blazar BR, Tolar J.

Hum Gene Ther. 2011 Sep;22(9):1155-65. doi: 10.1089/hum.2011.072. Epub 2011 Aug 10.

48.

B-cell receptors and heavy chain diseases: guilty by association?

Corcos D, Osborn MJ, Matheson LS.

Blood. 2011 Jun 30;117(26):6991-8. doi: 10.1182/blood-2011-02-336164. Epub 2011 Apr 20. Review.

PMID:
21508409
49.

Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa.

Tolar J, Xia L, Riddle MJ, Lees CJ, Eide CR, McElmurry RT, Titeux M, Osborn MJ, Lund TC, Hovnanian A, Wagner JE, Blazar BR.

J Invest Dermatol. 2011 Apr;131(4):848-56. doi: 10.1038/jid.2010.346. Epub 2010 Dec 2.

50.

Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I.

Osborn MJ, McElmurry RT, Lees CJ, DeFeo AP, Chen ZY, Kay MA, Naldini L, Freeman G, Tolar J, Blazar BR.

Mol Ther. 2011 Mar;19(3):450-60. doi: 10.1038/mt.2010.249. Epub 2010 Nov 16.

Supplemental Content

Loading ...
Support Center